Previous close | 12.00 |
Open | 11.80 |
Bid | 12.10 x N/A |
Ask | 12.20 x N/A |
Day's range | 11.80 - 11.80 |
52-week range | 2.10 - 17.20 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SEATTLE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that its senior management will participate in panel discussions and company presentations at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit in New York, NY on October 8, 2024 and the JonesResearch Virtual Radioph
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company will present updated preclinical data on PSV359 at the 37th Annual Congress of the European Association of Nuclear Medicine (“EANM”), which is being held in Hamburg, Germany, from October 19-23, 2024. Presentations regarding ce
SEATTLE, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced updates featuring the Company’s alpha-particle radiopharmaceuticals at the World Molecular Imaging Congress (WMIC) 2024, held on September 9-13, 2024, in Québec, Canada. “We are pleased with the additional data that support the continued d